SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Clinical trials for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising cancer combo trial halted early
Disease control TerminatedThis study tested whether adding the drug Debio 1143 (Xevinapant) to standard chemoradiation helps people with advanced head and neck cancer live longer without the disease getting worse. The trial planned to enroll 730 adults with untreated, locally advanced squamous cell carcin…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis study tested a new drug, PF-08046052/SGN-EGFRd2, in people with advanced solid tumors like colorectal, lung, head and neck, and pancreatic cancers that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The study was terminated e…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
Pfizer's new cancer drug trial halted early after testing in just 10 patients
Disease control TerminatedThis early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, colon, kidney, and ovarian cancers. The goal was to check safety, find the right dose, and see if the drug shrinks tumors. O…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
Pfizer cancer drug trial halted early after only 9 patients
Disease control TerminatedThis early-stage study tested a new experimental drug (PF-07820435) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, skin, and kidney cancers. The goal was to check safety and find the right dose. Only 9 people took part before the study was…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
Early trial tests new drug combo for tough head & neck cancers
Disease control TerminatedThis early-stage study aimed to find a safe dose for combining a new immunotherapy drug (pembrolizumab) with standard chemotherapy and radiation in patients with advanced head and neck cancer. The main goal was to check if the combination caused acceptable side effects, especiall…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Apr 09, 2026 19:34 UTC